Optimizing medical therapy for gastroesophageal reflux disease: State of the art

Reviews in Gastroenterological Disorders

Volumn 3, Issue 2, 2003, Pages 59-69

  Katz, Philip O ^a  

^a GRADUATE HOSPITAL   (United States)

Author keywords

Erosive esophagitis; Gastroesophageal reflux disease; H2 receptor antagonist; Proton pump inhibitor

Indexed keywords

ACETYLCHOLINE; ALGINIC ACID; ANTACID AGENT; BENZIMIDAZOLE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CISAPRIDE; DOMPERIDONE; ESOMEPRAZOLE; FAMOTIDINE; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PHENYTOIN; PROCAINAMIDE; PROKINETIC AGENT; PROTON PUMP; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SEDATIVE AGENT; STOMACH SECRETION INHIBITOR; SUCRALFATE; TEGASEROD; THEOPHYLLINE; UNINDEXED DRUG;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; AMENORRHEA; ANXIETY DISORDER; BREAST TENDERNESS; CONFUSION; CONSTIPATION; DEPRESSION; DIET THERAPY; DROWSINESS; DRUG ABSORPTION; DRUG BINDING; GALACTORRHEA; GASTROESOPHAGEAL REFLUX; HALLUCINATION; HEART DISEASE; HUMAN; HYPERPROLACTINEMIA; LIFESTYLE; NAUSEA; PRACTICE GUIDELINE; RESTLESSNESS; REVIEW; SMOKING CESSATION; STOMACH ACID SECRETION; STOMACH PH; SYMPTOMATOLOGY; TARDIVE DYSKINESIA;

ADULT; AGED; ANTI-ULCER AGENTS; DIET; ENZYME INHIBITORS; ESOPHAGITIS, PEPTIC; FEMALE; GASTRIC MUCOSA; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HUMANS; HYDROGEN-ION CONCENTRATION; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT OUTCOME;

EID: 0037840284     PISSN: 1533001X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999;94:1434-1442.
2. Chiba N, De Gara CJ, Wilkonson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology. 1997;112:1798-1810.
3. Tytgat GNJ, Nio CY. The medical therapy of reflux oesophagitis. Bailleres Clin Gastroenterol. 1987;1:791-807.
4. Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacologic management of gastro-oesophageal reflux disease. Drugs. 1995; 49:695-710.
5. Elsborg L, Beck B, Stubgaard M. Effect of sucralfate on gastroesophageal reflux in esophagitis. Hepatogastroenterology. 1985;32:181-184.
6. Simon B, Mueller P. Comparison of the effect of sucralfate and ranitidine in reflux esophagitis. Am J Med. 1987;83:43-47.
7. Hameeteman W, van de Boomgaard DM, Dekker W, et al. Sucralfate versus cimetidine in reflux esophagitis: single blind multicenter study. J Clin Gastroenterol. 1987;9:390-394.
8. Barone JA, Jessen LM, Colaizzi JL, Bierman RH. Cisapride: a gastrointestinal prokinetic drug. Ann Pharmacother. 1994;28:488-500.
9. McCallum RW, Ippoliti AF, Cooner C, et al. A controlled trial of metoclopramide in symptomatic gastroesophageal reflux. N Engl J Med. 1977;296:354-357.
10. Bright-Asare P, El-Bassoussi M. Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterol. 1980;2:149-156.
11. Temple JG, Bradby GVH, O'Connor F, et al. Cimetidine and metoclopramide in esophageal reflux disease. Br Med J. 1983;286:1863-1864.
12. Paull A, Kerr A, Grant AK. A controlled trial of metoclopramide in reflux esophagitis. Med J Australia. 1974;2:627-629.
13. Venables CW, Bell D, Eccleston D. A double-blind study of metoclopramide in symptomatic peptic esophagitis. Postgrad Med J. 1973;49(suppl 4):73-77.
14. Ramirez B, Richter JE. Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1993;7:5-20.
15. Blackwell JN, Heading RC, Fettes MR. Effects of domperidone on lower oesophageal sphincter pressure and gastro-oesophageal reflux in patients with peptic esophagitis. Progress with domperidone. Royal Society of Medicine. International Congress and Symposium Series. 1981;36:57.
16. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ. The partial 5HT4 against HTC 919 reduced acid reflux parameters in patients with GERD. Gastroenterology. 1999;116:G0881.
17. Bell NJV, Burger DL, Howden CW, et al. Appropriate acid suppression for the management of gastro-esophageal reflux disease. Digestion. 1992;51(suppl 1):59-67.
18. Jones DB, Howden CW, Burget DW, et al. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut. 1987;28:1120-1127.
19. DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch Intern Med. 1995;155:2165-2173.
20. Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut. 1992;33:118-124.
21. Cloud ML, Offen WW. Nizatidine versus placebo in gastroesophageal reflux disease: a six-week, multicenter, randomized, double-blind comparison. Dig Dis Sci. 1992;37:865-874.
22. McCarty-Dawson D, Sue S, Morrill B, Murdock RH Jr. Ranitidine versus cimetidine in the healing of erosive esophagitis. Clin Ther. 1996;18:1150-1160.
23. Roufail W, Belsito A, Robinson M, et al. Ranitidine for erosive esophagitis: a double-blind, placebo controlled study. Aliment Pharmacol Ther. 1992;6:597-607.
24. Simon TJ, Roberts WG, Berlin RG, et al. Acid suppression by famotidine 20 mg twice daily or 40 mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis. Clin Ther. 1995;17:1147-1156.
25. Wesdorp ICE, Dekker W, Festen HPM. Efficacy of famotidine 20 mg twice a day versus 40 mg twice a day in the treatment of erosive or ulcerative reflux esophagitis. Dig Dis Sci. 1993;38:2287-2293.
26. Euler AR, Murdock RH Jr, Wilson TH, et al. Ranitidine is effective therapy for erosive esophagitis. Am J Gastroenterol. 1993;88:520-524.
27. Feldman M, Burton ME. Histamine2-receptor antagonists: standard therapy for acid-peptic diseases. N Engl J Med. 1990;323:1672-1680.
28. Lipsy RJ, Fennerty B, Fagan TC. Clinical review of histamine2 receptor antagonists. Arch Intern Med. 1990;150:745-751.
29. Robinson M. Review article: current perspectives on hypergastrinemia and enterochromaffin-like-cell hyperplasia. Aliment Pharmacol Ther. 1999;13(suppl 5):5-10.
30. Massoomi F, Savage J, Destache CJ. Omeprazole: a comprehensive review. Pharmacotherapy. 1993;13:46-59.
31. Lew EA. Review article: pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther. 1999:13(suppl 5):11-16.
32. Tutuian R, Katz PO, Castell DO. A PPI is a PPI: lessons learned from intragastric pH monitoring [abstract]. Gastroenterology. 2000;118:A17.
33. Miner PB, Katz PO, Chen Y, Sostek M. Esomeprazole provides more effective intragastric pH control than standard doses of other proton pump inhibitors [abstract]. Gastroenterology. In press.
34. Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive esophagiris. Am J Gastroenterol. 1996;91:1749-1758.
35. Richter JE, Kahrilas PJ, Sontag SJ, et al. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized controlled trial in erosive esophagitis patients. Am J Gastroenterol. 2001;96:3089-3098.
36. Mossner J, Holscher AH, Herz R, et al. A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther. 1995;9:321-326.
37. Dekkers CPM, Beker JA, Thjodleifsson B, et al. Double-blind comparison of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1999;13:49-57.
38. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-583.
39. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled study. Am J Gastroenterol. 2001;96:656-665.
40. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux esophagitis patients; a randomized, controlled trial. Aliment Pharmacol Ther. 2000;14:1249-1258.
41. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999;45:172-180.
42. Sontag SJ, Hirschowitz BJ, Holt S, et al. Two doses of omeprazole versus placebo in symptomatic erosive esophagitis: the US Multicenter study. Gastroenterology. 1992;102:109-118.
43. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661-669.
44. Hatlebakk JG, Katz PO, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000; 14:1267-1272.
45. Kuo B, Castell DO. Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol. 1996;91:1532-1538.
46. Hatlebakk JG, Katz PO, Kuo B, et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther. 1998; 12:1235-1240.
47. Pehlivanov N, Olyaee M, Sarosiek l, et al. Evening vs morning dose of rabeprazole in GERD patients to control esophageal acid exposure [abstract]. Am J Gastroenterol. 2002;97(suppl):S4.
48. Katz PO, Hatlebakk JG, Castell DO. Gastric acidity and acid breakthrough with twice daily omeprazole or lansoprazole. Aliment Pharmacol Ther. 2000;14:709-714.
49. Howden CW, Henning JM, Huang B, et al. Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol. 2001;96:1704-1710.
50. Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology. 2001;121:1095-1100.
51. Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93:763-767.
52. Katz PO, Anderson C, Khoury R, et al. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther. 1998;12:1231-1234.
53. Katz P, Castell DO, Chen Y, Sostek M. Esomeprazole 40 mg twice daily maintains intragastric pH > 4 more than 80% of a 24 hour time period. Am J Gastroenterol. In press.
54. Hatlebakk J, Katz PO, Castell DO. Medical therapy. Management of the refractory patient. Gastroenterol Clin N Am. 1999;28:847-860.
55. Fass R, Sampliner RE, Malagon IB, et al. Failure of acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther. 2000;14:597-602.
56. Leite LP, Johnston BT, Barrett J, et al. Persistent acid secretion during omeprazole therapy: a study of gastric acid profiles in patients demonstrating failure of omeprazole therapy. Am J Gastroenterol. 1996;91:1527-1531.
57. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-632.
58. Katz PO, Xue S, Castell DO. Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg. Aliment Pharmacol Ther. 2001;15:647-652.